FFRangio System vs Lung AI

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

FFRangio System

by CathWorks (acquired by Medtronic)

Lung AI

by Multiple (e.g., RevealDx, Optellum, LungLife AI, Qure.ai, Arterys, DeepHealth, HeartLung.AI)

AI Verdict

Tool A, the FFRangio System, is specifically designed for optimizing percutaneous coronary intervention (PCI) decisions by providing wire-free FFR guidance for patients with coronary artery disease. In contrast, Tool B, Lung AI, offers a handheld ultrasound platform with AI for real-time diagnostic imaging and detection of various cardiac and lung conditions. While both leverage AI in cardiology, their primary applications and technological modalities are distinct, making them suitable for different clinical needs.

Choose FFRangio System if…

Choose the FFRangio System if your cardiology department requires precise, wire-free functional assessment of coronary artery disease to optimize percutaneous coronary intervention (PCI) decisions. This system is ideal for cath labs seeking to quickly obtain multi-vessel FFR results and advanced insights, such as lesion impact and non-invasive sizing, without the need for invasive pressure wires or pharmacological agents.

View FFRangio System →

Choose Lung AI if…

Choose Lung AI if your healthcare professionals need a portable, AI-powered handheld ultrasound solution for rapid, real-time diagnostic decisions at the point of care. This tool is particularly well-suited for emergency medicine, pulmonology, or cardiology settings where quick detection of conditions like pleural effusion, consolidation, or indicators of heart failure is critical, leveraging on-device AI for immediate insights.

View Lung AI →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	FFRangio System	Lung AI
Pricing	Contact vendor for pricing information.	Unknown
Deployment	SaaS, on-prem, hybrid	Cloud-based, integrated with existing platforms (e.g., RapidAI), and potentially on-premise.
BAA Available	Yes AI-estimated	Unknown
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Lung AI

While both tools emphasize ease of use, Tool B (Exo Iris with Lung AI) has a stronger focus on making advanced imaging accessible to a broader range of healthcare professionals. Its handheld, smartphone-like interface, guided image capture, and integrated AI-powered education (Exo U) provide a comprehensive approach to user empowerment and accessibility for diverse clinical settings.

Clinical Value

FFRangio System

Both tools offer significant clinical value in their respective domains. However, Tool A (FFRangio System) provides a non-invasive, wire-free, and drug-free alternative to a traditionally invasive procedure (wire-based FFR) for guiding critical PCI decisions. It has strong clinical evidence demonstrating comparable outcomes and diagnostic accuracy to the gold standard, representing a profound shift in an established, high-stakes interventional procedure.

Pricing & Value

Lung AI

While both require contacting for specific pricing, Tool B (Exo Iris with Lung AI) explicitly markets itself as affordable, with a published starting price for the device and a clear subscription model for its software and AI features. This transparency and emphasis on cost-effectiveness, especially compared to traditional ultrasound systems, suggests a higher value proposition and broader accessibility for point-of-care applications.

Enterprise Readiness

Lung AI

Tool B (Exo Iris with Lung AI) demonstrates superior enterprise readiness due to its explicit HIPAA, HITRUST, SOC2 Type II compliance, and ISO 27001 certification. Its on-device AI processing allows for operation without an internet connection, enhancing reliability and data security in diverse clinical environments. The comprehensive workflow solution (Exo Works) further supports enterprise-level POCUS programs.

Innovation

Tie

Both tools represent significant innovations in their respective fields. Tool A (FFRangio System) offers a groundbreaking wire-free and drug-free approach to FFR, transforming an invasive interventional cardiology procedure into a less invasive, AI-driven assessment. Tool B (Exo Iris with Lung AI) innovates by democratizing advanced AI-powered ultrasound imaging through a high-performance, handheld device with on-device processing and guided capture, making sophisticated diagnostics accessible at the point of care.

Support & Docs

Lung AI

Tool B (Exo Iris with Lung AI) clearly excels in this dimension by explicitly offering 'Exo U,' an AI-powered education and training platform designed to simplify POCUS learning and adoption. Additionally, Exo provides a robust and easily accessible support center with various contact methods and comprehensive user manuals, demonstrating a strong commitment to user support and documentation.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	FFRangio System	Lung AI
Name	FFRangio System	Lung AI
Company	CathWorks	Exo
Description	The CathWorks FFRangio System delivers wire-free and drug-free 3D FFR guidance, providing accurate multi-vessel FFR results and advanced insights to quickly optimize and confirm PCI decisions for patients with coronary artery disease.	Exo is pioneering a high-performance, handheld ultrasound platform that uses artificial intelligence for imaging and therapeutic applications. By delivering affordable, easy-to-use medical imaging, Exo empowers healthcare professionals around the world to make critical, real-time decisions that improve patient outcomes.
Core Functionality	Provides real-time FFRangio values, simulated pullback curves, lesion impact assessment, and integrated sizing tools for coronary artery disease, eliminating the need for invasive pressure wires, drugs, or a guide catheter.	Offers AI-powered detection of pleural effusion and consolidation/atelectasis, real-time feedback and image quality monitoring (SweepAI), automated AI-based indicators for cardiac conditions, and guided image capture for optimal scans.
Specialties	Cardiology	Cardiology, Emergency Medicine, Pulmonology

Videos

Demos, reviews, and walkthroughs featuring FFRangio System and Lung AI.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows for cardiac assessment and intervention?

The FFRangio System is designed for seamless integration with cath lab boom and PACS, providing real-time FFR guidance during PCI procedures to optimize decision-making. Lung AI, as a handheld ultrasound, offers real-time, on-device AI analysis for point-of-care decisions in various settings, including cardiac and lung scanning, with guided image capture for optimal results.

What is the depth of integration with existing hospital information systems, specifically regarding data transfer to the EHR or PACS?

The FFRangio System offers seamless integration with PACS, facilitating data transfer within the cath lab environment. Lung AI operates with on-device AI processing, which means its primary data processing occurs locally on the handheld device, and the provided information does not explicitly detail its direct integration with EHR or PACS for data transfer.

How does each tool's AI-driven analysis compare in terms of accuracy and sensitivity for its specific diagnostic applications?

The FFRangio System has demonstrated high diagnostic accuracy, with reported per-vessel sensitivity of 94% and specificity of 91% for predicting FFR compared to pressure wire-derived FFR. Lung AI offers AI-powered detection of pleural effusion and consolidation/atelectasis, and automated AI-based indicators for cardiac conditions, with AI models for lung nodule detection generally showing higher sensitivity but sometimes lower specificity compared to radiologists.

What is the expected learning curve for physicians and their teams to become proficient with each system, and how quickly can clinical benefits be realized?

The FFRangio System features an intuitive user interface and AI to aid in quick angiogram analysis, with studies suggesting initial training enables quick attainment of maximal performance. Lung AI emphasizes easy-to-use medical imaging, guided image capture, and offers Exo U for AI-powered POCUS education and training, aiming for rapid adoption and real-time decision support.

What additional security measures, beyond standard compliance, are in place to protect patient data and ensure system integrity for each tool?

The FFRangio System is ISO 27001 certified for information security, indicating a robust framework for managing information security risks. Lung AI utilizes on-device AI processing, which means it operates without an internet connection, potentially enhancing data security by keeping patient information local to the device.

Do these systems offer robust audit-trail features to track user interactions, data access, and changes for clinical and administrative oversight?

The provided information does not explicitly detail specific audit-trail features for either the FFRangio System or Lung AI. However, robust audit trails are generally crucial for healthcare AI systems to track user interactions, data access, and changes for compliance and accountability.